Roche Media November 18, 2025 Roche's oral SERD goes 2 for 2, hitting goal in phase 3 adjuvant breast cancer trial - Fierce Biotech Roche's oral SERD goes 2 for 2, hitting goal in phase 3 adjuvant breast cancer trial Fierce Biotech